ДАРАТУМУМАБ В ЛЕЧЕНИИ МНОЖЕСТВЕННОЙ МИЕЛОМЫ

СтатьяМЕД СОВЕТ. 2017; № 14: 94–102. DOI:10.21518/2079-701X-2017-14-94-102

Рыжко В.В.^[1]

Канаева М.Л.^[1]

^[1]Национальный медицинский исследовательский центр гематологии (Москва)

Применение в клинической практике препаратов из класса ингибиторов протеасом и иммуномодуляторов в последние десятилетия способствовало значительному повышению выживаемости пациентов с множественной миеломой. Вместе с тем сохраняется потребность во внедрении новых классов препаратов в клиническую практику вследствие рецидивирующего течения заболевания. В 2015 г. FDA (США) были одобрены к применению у пациентов с рецидивирующей множественной миеломой два препарата из класса моноклональных антител, и за короткий период иммунотерапия стала неотъемлемым компонентом лечения таких больных.

В статье представлен анализ данных научных публикаций относительно механизма действия, безопасности применения и клинической эффективности даратумумаба, препарата из класса моноклональных антител, специфичных по отношению к опухолевому белку CD38, при лечении пациентов с множественной миеломой.

В России даратумумаб зарегистрирован (РУ ЛП-004367 от 07.07.2017) и показан в качестве монотерапии у пациентов с рецидивирующей или рефрактерной множественной миеломой, предшествующее лечение которых включало ингибиторы протеасом и иммуномодулирующие препараты.

Даратумумаб продемонстрировал благоприятный профиль безопасности. На фоне применения даратумумаба основные нежелательные явления включали умеренно выраженные реакции, связанные с инфузионным введением препарата, развивавшиеся преимущественно во время первой инфузии.

множественная миелома

даратумумаб

белок CD38

моноклональные антитела

Антитела моноклональные

Безопасность

Больные

Бортезомиб

Время

Выживаемость

Данных анализ

Дексаметазон

Издания

Иммуномодуляторы

Иммунотерапия

Карповые

Клетки

Клиническое исследование

Кровь

Леналидомид

Миелома множественная

Научные коммуникации

Российская Федерация

Чувствительность и специфичность

Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood, 2008, 111(5): 2516–2520.

Moreau P, Touzeau C. Multiple myeloma: from front-line to relapsed therapies. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Meet, 2015: e504–511.

Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia, 2012, 26(1): 149–157.

Tai Y-T, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibodydependent cellular cytotoxicity in the bone marrow milieu. Blood, 2008, 112(4): 1329–1337.

Van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther, 2009, 8(9): 2616–2624.

Jakubowiak A, Offidani M, Pégourie B, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/ dexamethasone for relapsed/-refractory MM. Blood, 2016, 127(23): 2833–2840.

Richardson PG, Jagannath S, Moreau P, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 doseescalation study. Lancet Haematol, 2015, 2(12): e516–527.

Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med, 2015, 373(7): 621–631.

Malavasi F, Deaglio S, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev, 2008, 88(3): 841–886.

Van De Donk NWCJ, Janmaat ML, Mutis T, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev, 2016, 270(1): 95–112.

Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol, 2004, 121(4): 482–488.

De Weers M, Tai Y-T, van der Veer MS, et al. Daratumumab, a noveltherapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol Baltim Md 1950, 2011, 186(3): 1840–1848.

Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. Mabs, 2015, 7(2): 311–321.

Overdijk MB, Jansen JHM, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via fcγ receptor-mediated cross-linking. J Immunol Baltim Md 1950, 2016, 197(3): 807–813.

Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38 immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood, 2016, 128(3): 384–394.

Feng X, Zhang L, Acharya C, et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res Off J Am Assoc Cancer Res, 2017.

Nijhof IS, Groen RWJ, Noort WA, et al. Preclinical evidence for the therapeutic potential of CD38targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res Off J Am Assoc Cancer Res, 2015, 21(12): 2802–2810.

Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med, 2015, 373(13): 1207–1219.

Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet Lond Engl, 2016, 387 (10027): 1551–1560.

Plesner T, Arkenau H-T, Gimsing P, et al. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood, 2016.

Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood, 2016.

Nijhof IS, Casneuf T, Van Velzen J, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood, 2016, 128(7): 959–970.

Boyle EM, Petillon M-O, Herbaux C, et al. Daratumumab in combination with dexamethasone in resistant or refractory multiple myeloma: primary results of the IFM2014-04 Trial. Blood, 2016, 128(22): 2138–2138.

Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med, 2016, 375(14): 1319–1331.

Moreau P, Kaufman JL, Sutherland HJ, et al. Efficacy of daratumumab, lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone for relapsed or refractory multiple myeloma among patients with 1 to 3 prior lines of therapy based on previous treatment exposure: updated analysis of pollux. Blood, 2016, 128(22): 489–489.

Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med, 2016, 375(8): 754–766.

Mateos M-V, Estell J, Barreto W, et al. Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of castor. Blood, 2016, 128 (22): 1150–1150.

Avet-Loiseau H, Casneuf T, Chiu C, et al. Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus dexamethasone or bortezomib plus dexamethasone. Blood, 2016, 128(22): 246–246.

Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol, 2017, 3(1): 28–35.

Oostendorp M, Lammerts Van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion (Paris), 2015, 55(6 Pt 2): 1555–1562.

Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion (Paris),2015, 55(6 Pt 2): 1545–1554.

Chapuy CI, Aguad MD, Nicholson RT, et al. International validation of a dithiothreitol (DTT)based method to resolve the daratumumab interference with blood compatibility testing. Transfusion (Paris), 2016, 56(12): 2964–2972.

Moreau P, Van De Donk NWCJ, San Miguel J, et al. Practical considerations for the use of daratumumab, a Novel CD38 monoclonal antibody, in Myeloma. Drugs, 2016, 76(8): 853–867.

Van De Donk NWCJ, Otten HG, El Haddad O, et al. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin Chem Lab Med, 2016, 54(6): 1105–1109.

Kumar S, Paiva B, Anderson KC, et al. International Myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol, 2016, 17(8): e328–346.

Nooka AK, Joseph N, Boise LH, et al. Clinical efficacy of daratumumab, pomalidomide and dexamethasone in relapsed, refractory myeloma patients: utility of retreatment with daratumumab among refractory patients. Blood, 2016, 128(22): 492–492.

Usmani SZ, Nahi H, Mateos M-V, et al. Openlabel, multicenter, dose escalation Phase 1b исследование to assess the subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple Myeloma (PAVO). Blood, 2016, 128(22): 1149–1149.

Fernández De Larrea C, Kyle RA, Durie BGM, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the international Myeloma working group. Leukemia, 2013, 27(4): 780–791.

Martin TG, Mannis GN, Chari A, et al. Phase Ib study of isatuximaband carfilzomib in relapse and refractory multiple Myeloma. Blood, 2016, 128(22): 2111–2111.

Moreno L, Zabaleta A, Alignani D, et al. Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 monoclonal antibody isatuximab in Multiple Myeloma (MM). Blood, 2016, 128(22): 2105–2105.

Richardson PG, Mikhael J, Usmani SZ, et al. Preliminary results froma Phase Ib Study of isatuximab in combination with pomalidomide and dexamethasone in relapsed and refractory multiple myeloma. Blood. 2016, 128(22): 2123–2123.

Raab MS, Chatterjee M, Goldschmidt H, et al. A Phase I/IIa study of the CD38 antibody MOR202 alone and in combination with pomalidomide or lenalidomide in patients with relapsed or refractory multiple myeloma. Blood. 2016, 128(22): 1152–1152.

Язык текста: Русский

ISSN: 2079-701X